Tegoprubart
Kidney Transplant Rejection Prevention
Key Facts
About Eledon Pharmaceuticals
Eledon Pharmaceuticals is a clinical-stage biotech focused on developing tegoprubart, an anti-CD40L antibody, to prevent organ transplant rejection and treat autoimmune/neurodegenerative diseases. Its core strategy is to disrupt the CD40/CD40L costimulatory pathway, potentially offering a safer, more effective alternative to current immunosuppressants. The company has completed a Phase 2 trial (BESTOW) in kidney transplantation and is advancing multiple investigator-sponsored and partnered programs, positioning itself at the forefront of next-generation transplant medicine.
View full company profileAbout Eledon Pharmaceuticals
Eledon Pharmaceuticals is a clinical-stage biotech focused on developing tegoprubart, an anti-CD40L antibody, to prevent organ transplant rejection and treat autoimmune/neurodegenerative diseases. Its core strategy is to disrupt the CD40/CD40L costimulatory pathway, potentially offering a safer, more effective alternative to current immunosuppressants. The company has completed a Phase 2 trial (BESTOW) in kidney transplantation and is advancing multiple investigator-sponsored and partnered programs, positioning itself at the forefront of next-generation transplant medicine.
View full company profileAbout Eledon Pharmaceuticals
Eledon Pharmaceuticals is a clinical-stage biotech focused on developing tegoprubart, an anti-CD40L antibody, to prevent organ transplant rejection and treat autoimmune/neurodegenerative diseases. Its core strategy is to disrupt the CD40/CD40L costimulatory pathway, potentially offering a safer, more effective alternative to current immunosuppressants. The company has completed a Phase 2 trial (BESTOW) in kidney transplantation and is advancing multiple investigator-sponsored and partnered programs, positioning itself at the forefront of next-generation transplant medicine.
View full company profileAbout Eledon Pharmaceuticals
Eledon Pharmaceuticals is a clinical-stage biotech focused on developing tegoprubart, an anti-CD40L antibody, to prevent organ transplant rejection and treat autoimmune/neurodegenerative diseases. Its core strategy is to disrupt the CD40/CD40L costimulatory pathway, potentially offering a safer, more effective alternative to current immunosuppressants. The company has completed a Phase 2 trial (BESTOW) in kidney transplantation and is advancing multiple investigator-sponsored and partnered programs, positioning itself at the forefront of next-generation transplant medicine.
View full company profileAbout Eledon Pharmaceuticals
Eledon Pharmaceuticals is a clinical-stage biotech focused on developing tegoprubart, an anti-CD40L antibody, to prevent organ transplant rejection and treat autoimmune/neurodegenerative diseases. Its core strategy is to disrupt the CD40/CD40L costimulatory pathway, potentially offering a safer, more effective alternative to current immunosuppressants. The company has completed a Phase 2 trial (BESTOW) in kidney transplantation and is advancing multiple investigator-sponsored and partnered programs, positioning itself at the forefront of next-generation transplant medicine.
View full company profileAbout Eledon Pharmaceuticals
Eledon Pharmaceuticals is a clinical-stage biotech focused on developing tegoprubart, an anti-CD40L antibody, to prevent organ transplant rejection and treat autoimmune/neurodegenerative diseases. Its core strategy is to disrupt the CD40/CD40L costimulatory pathway, potentially offering a safer, more effective alternative to current immunosuppressants. The company has completed a Phase 2 trial (BESTOW) in kidney transplantation and is advancing multiple investigator-sponsored and partnered programs, positioning itself at the forefront of next-generation transplant medicine.
View full company profileAbout Eledon Pharmaceuticals
Eledon Pharmaceuticals is a clinical-stage biotech focused on developing tegoprubart, an anti-CD40L antibody, to prevent organ transplant rejection and treat autoimmune/neurodegenerative diseases. Its core strategy is to disrupt the CD40/CD40L costimulatory pathway, potentially offering a safer, more effective alternative to current immunosuppressants. The company has completed a Phase 2 trial (BESTOW) in kidney transplantation and is advancing multiple investigator-sponsored and partnered programs, positioning itself at the forefront of next-generation transplant medicine.
View full company profileAbout Eledon Pharmaceuticals
Eledon Pharmaceuticals is a clinical-stage biotech focused on developing tegoprubart, an anti-CD40L antibody, to prevent organ transplant rejection and treat autoimmune/neurodegenerative diseases. Its core strategy is to disrupt the CD40/CD40L costimulatory pathway, potentially offering a safer, more effective alternative to current immunosuppressants. The company has completed a Phase 2 trial (BESTOW) in kidney transplantation and is advancing multiple investigator-sponsored and partnered programs, positioning itself at the forefront of next-generation transplant medicine.
View full company profileAbout Eledon Pharmaceuticals
Eledon Pharmaceuticals is a clinical-stage biotech focused on developing tegoprubart, an anti-CD40L antibody, to prevent organ transplant rejection and treat autoimmune/neurodegenerative diseases. Its core strategy is to disrupt the CD40/CD40L costimulatory pathway, potentially offering a safer, more effective alternative to current immunosuppressants. The company has completed a Phase 2 trial (BESTOW) in kidney transplantation and is advancing multiple investigator-sponsored and partnered programs, positioning itself at the forefront of next-generation transplant medicine.
View full company profileAbout Eledon Pharmaceuticals
Eledon Pharmaceuticals is a clinical-stage biotech focused on developing tegoprubart, an anti-CD40L antibody, to prevent organ transplant rejection and treat autoimmune/neurodegenerative diseases. Its core strategy is to disrupt the CD40/CD40L costimulatory pathway, potentially offering a safer, more effective alternative to current immunosuppressants. The company has completed a Phase 2 trial (BESTOW) in kidney transplantation and is advancing multiple investigator-sponsored and partnered programs, positioning itself at the forefront of next-generation transplant medicine.
View full company profileTherapeutic Areas
Other Kidney Transplant Rejection Prevention Drugs
| Drug | Company | Phase |
|---|---|---|
| Tolerance Induction Therapy | ImmunoFree | Phase 2 |